These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6865964)

  • 21. Tranylcypromine isomers in Parkinson's disease. Effect of low doses on monoamine oxidase inhibition and blood pressure response.
    Riederer P; Reynolds GP; Jellinger K; Seemann D; Danielczyk W
    Mod Probl Pharmacopsychiatry; 1983; 19():154-61. PubMed ID: 6865963
    [No Abstract]   [Full Text] [Related]  

  • 22. Tranylcypromine in recurrent brief depression: two case reports.
    Joffe RT
    Int Clin Psychopharmacol; 1996 Dec; 11(4):287-8. PubMed ID: 9031997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Winter depression responds to an open trial of tranylcypromine.
    Dilsaver SC; Jaeckle RS
    J Clin Psychiatry; 1990 Aug; 51(8):326-9. PubMed ID: 2199430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl.
    Murphy DL; Tamarkin L; Sunderland T; Garrick NA; Cohen RM
    Psychiatry Res; 1986 Feb; 17(2):119-27. PubMed ID: 3008207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet monoamine oxidase inhibition as a potential indicator of favorable response to MAOI's in geriatric depressions.
    Georgotas A; Mann J; Friedman E
    Biol Psychiatry; 1981 Oct; 16(10):997-1001. PubMed ID: 7306621
    [No Abstract]   [Full Text] [Related]  

  • 26. Monoamine oxidase activity in platelets before and after sleep deprivation as predictor for antidepressive drug response.
    Fähndrich E; Müller-Oerlinghausen B
    Mod Probl Pharmacopsychiatry; 1983; 19():327-36. PubMed ID: 6865972
    [No Abstract]   [Full Text] [Related]  

  • 27. Monoamine oxidase activity in blood platelets from patients with cyclophrenic depressive syndromes.
    Landowski J; Lysiak W; Angielski S
    Biochem Med; 1975 Dec; 14(4):347-54. PubMed ID: 1227511
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoinduction of hypertensive reactions by tranylcypromine?
    Keck PE; Pope HG; Nierenberg AA
    J Clin Psychopharmacol; 1989 Feb; 9(1):48-51. PubMed ID: 2486182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAO inhibition and clinical response in depressed patients treated with phenelzine.
    Bresnahan DB; Pandey GN; Janicak PG; Sharma R; Boshes RA; Chang SS; Gierl BL; Davis JM
    J Clin Psychiatry; 1990 Feb; 51(2):47-50. PubMed ID: 2298705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tranylcypromine and inhibition of MAO activity.
    Bowden CL
    J Clin Psychopharmacol; 1984 Jun; 4(3):172-3. PubMed ID: 6736280
    [No Abstract]   [Full Text] [Related]  

  • 32. Platelet monoamine oxidase in unipolar and bipolar depression.
    Trivedi JK; Lal N; Singh RP; Viswanathan PN
    Indian J Med Res; 1988 Aug; 88():165-8. PubMed ID: 3198176
    [No Abstract]   [Full Text] [Related]  

  • 33. Tranylcypromine: patterns and predictors of response.
    White K; White J
    J Clin Psychiatry; 1986 Jul; 47(7):380-2. PubMed ID: 3522559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tranylcypromine withdrawal phenomena.
    Halle MT; Dilsaver SC
    J Psychiatry Neurosci; 1993 Jan; 18(1):49-50. PubMed ID: 8461282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet MAO in functional psychoses with evidence of brain atrophy.
    Luchins DJ; Arora RC; Meltzer HY
    Am J Psychiatry; 1985 Aug; 142(8):996-7. PubMed ID: 4025609
    [No Abstract]   [Full Text] [Related]  

  • 36. Tranylcypromine plus risperidone for treatment-refractory major depression.
    Stoll AL; Haura G
    J Clin Psychopharmacol; 2000 Aug; 20(4):495-6. PubMed ID: 10917417
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.
    Raft D; Davidson J; Wasik J; Mattox A
    Neuropsychobiology; 1981; 7(3):122-6. PubMed ID: 7231652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid antidepressant effect of addition of lithium to tranylcypromine.
    Tariot PN; Murphy DL; Sunderland T; Mueller EA; Cohen RM
    J Clin Psychopharmacol; 1986 Jun; 6(3):165-7. PubMed ID: 3711366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tranylcypromine treatment of major depression.
    Liebowitz MR
    J Clin Psychiatry; 1987 Jul; 48(7):303. PubMed ID: 3597337
    [No Abstract]   [Full Text] [Related]  

  • 40. A double-blind study of tranylcypromine treatment of major anergic depression.
    Himmelhoch JM; Fuchs CZ; Symons BJ
    J Nerv Ment Dis; 1982 Oct; 170(10):628-34. PubMed ID: 7050302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.